BACKGROUND: Inflammatory bowel disease (IBD) is the results of a chronic inflammatory process deriving from disequilibrium between self-microbiota composition and immune response. METHODS: New evidence, coming from Clostridium difficile infection, clearly showed that active and powerful modulation of microbiota composition by fecal microbiota composition (FMT) is safe, easy to perform, and efficacious, opening new frontiers in gastrointestinal and extra-intestinal diseases. FMT has been proposed also for IBD as well as other non-gastrointestinal conditions related to intestinal microbiota dysfunctions, with good preliminary data. RESULTS: In this setting, ulcerative colitis (UC) represents one of the most robust potential indications for FMT after C difficile colitis. CONCLUSIONS: In the present review, we focus on FMT and its application on ulcerative colitis, clarifying mechanisms of actions and efficacy data, trough completion of a meta-analysis on available randomized, controlled trial data in UC. Because microbiota is so crucially involved in this topic, a short review of microbial alterations in UC will also be performed.
BACKGROUND:Inflammatory bowel disease (IBD) is the results of a chronic inflammatory process deriving from disequilibrium between self-microbiota composition and immune response. METHODS: New evidence, coming from Clostridium difficileinfection, clearly showed that active and powerful modulation of microbiota composition by fecal microbiota composition (FMT) is safe, easy to perform, and efficacious, opening new frontiers in gastrointestinal and extra-intestinal diseases. FMT has been proposed also for IBD as well as other non-gastrointestinal conditions related to intestinal microbiota dysfunctions, with good preliminary data. RESULTS: In this setting, ulcerative colitis (UC) represents one of the most robust potential indications for FMT after C difficile colitis. CONCLUSIONS: In the present review, we focus on FMT and its application on ulcerative colitis, clarifying mechanisms of actions and efficacy data, trough completion of a meta-analysis on available randomized, controlled trial data in UC. Because microbiota is so crucially involved in this topic, a short review of microbial alterations in UC will also be performed.
Authors: E Nissilä; K Korpela; A I Lokki; R Paakkanen; S Jokiranta; W M de Vos; M-L Lokki; K-L Kolho; S Meri Journal: Clin Exp Immunol Date: 2017-09-25 Impact factor: 4.330
Authors: Ira Ekmekciu; Eliane von Klitzing; Christian Neumann; Petra Bacher; Alexander Scheffold; Stefan Bereswill; Markus M Heimesaat Journal: Front Microbiol Date: 2017-12-11 Impact factor: 5.640
Authors: Ira Ekmekciu; Eliane von Klitzing; Ulrike Fiebiger; Ulrike Escher; Christian Neumann; Petra Bacher; Alexander Scheffold; Anja A Kühl; Stefan Bereswill; Markus M Heimesaat Journal: Front Immunol Date: 2017-04-19 Impact factor: 7.561
Authors: Giovanni Cammarota; Gianluca Ianiro; Colleen R Kelly; Benjamin H Mullish; Jessica R Allegretti; Zain Kassam; Lorenza Putignani; Monika Fischer; Josbert J Keller; Samuel Paul Costello; Harry Sokol; Patrizia Kump; Reetta Satokari; Stacy A Kahn; Dina Kao; Perttu Arkkila; Ed J Kuijper; Maria J Gt Vehreschild; Cristina Pintus; Loris Lopetuso; Luca Masucci; Franco Scaldaferri; E M Terveer; Max Nieuwdorp; Antonio López-Sanromán; Juozas Kupcinskas; Ailsa Hart; Herbert Tilg; Antonio Gasbarrini Journal: Gut Date: 2019-09-28 Impact factor: 23.059